Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol.15 , Issue 1s (2026)
https://www.jneonatalsurg.com

OPEN ACCESS

Stem Cell Applications In Gynecology: Endometrial Regeneration And Ovarian Rejuvenation

Dr Muskaan Singhal [1], Dr Poonam Bhojwani [2], Dr Karuna Puri [3]

[1]Junior Resident NIMS Obgyn
Email: singhalmuss.3011@gmail.com
[2]NIMS Professor Obgyn
Email: poonambhojwani1@gmail.com
[3]MS Obgyn, Consultant and Owner Jyoti Prakash Hospital and IVF Centre Gurdaspur Punjab
Email: karuna04sharma@gmail.com

Cite this paper as: Dr Muskaan Singhal , Dr Poonam Bhojwani , Dr Karuna Puri (2026) Stem Cell Applications In Gynecology: Endometrial Regeneration And Ovarian Rejuvenation. Journal of Neonatal Surgery, 15, (1s) 119-130

ABSTRACT

Stem cell therapy has revolutionized the field of regenerative gynecology by offering new therapeutic possibilities for restoring fertility and repairing reproductive tissues that were once considered irreversibly damaged. The human endometrium and ovaries, being highly regenerative organs, are now recognized as potential targets for stem cell–based interventions aimed at treating disorders such as Asherman's syndrome, thin endometrium, and premature ovarian insufficiency. Various types of stem cells, including bone marrow–derived, adipose-derived, umbilical cord–derived, and menstrual blood–derived stem cells, have demonstrated remarkable potential in promoting endometrial regeneration and ovarian rejuvenation. These cells exert their effects through mechanisms such as cellular differentiation, paracrine signaling, angiogenesis, immunomodulation, and anti-fibrotic action. Advances in tissue engineering, gene editing, and exosome-based therapies are expanding the scope of clinical applications while minimizing ethical and immunological challenges. However, technical limitations, inconsistent methodologies, and insufficient long-term safety data continue to impede large-scale implementation. Ethical concerns and regulatory challenges further complicate clinical translation, necessitating standardized protocols and rigorous validation through multicentric randomized trials. Despite these challenges, the convergence of biotechnology, bioengineering, and molecular medicine holds the promise of making stem cell therapy an integral part of reproductive health management. Continued research into optimizing stem cell delivery, understanding molecular mechanisms, and integrating personalized medicine will determine the success of these innovative treatments in enhancing reproductive potential and quality of life for women worldwide...

Keywords: Stem cell therapy, Endometrial regeneration, Ovarian rejuvenation, Regenerative gynecology, Reproductive medicine

INTRODUCTION

Stem cell biology has rapidly evolved into one of the most promising frontiers in medical science, especially in the field of regenerative medicine. Stem cells are characterized by two fundamental properties the ability to self-renew and the potential to differentiate into specialized cell types. These unique capacities make them invaluable for replacing, repairing, or regenerating damaged tissues in the human body [1]. Within gynecology, stem cell–based regenerative therapies have emerged as potential game-changers in managing conditions such as endometrial atrophy, Asherman's syndrome, and premature ovarian insufficiency (POI). These disorders are among the leading causes of infertility and hormonal imbalance in women, and conventional treatment options often fail to restore natural function. Stem cell therapy has therefore introduced a new paradigm in reproductive medicine by harnessing the body's intrinsic potential for cellular regeneration [2]. Stem cells can be broadly categorized into embryonic stem cells (ESCs), adult stem cells, and induced pluripotent stem cells (iPSCs). Due to ethical limitations associated with ESCs, current human studies in gynecology focus primarily on adult and mesenchymal stem cells (MSCs). Mesenchymal stem cells, derived from sources such as bone marrow, adipose tissue, umbilical cord, and menstrual blood, have been shown to possess high proliferative, anti-inflammatory, and pro-angiogenic properties, making them suitable for human therapeutic use [3]. Moreover, endometrial-derived stem cells (EnSCs) have been identified as an easily accessible and highly regenerative source specific to the female reproductive system [4]. These cells can be isolated through minimally invasive procedures and have shown significant promise in clinical trials aimed at restoring endometrial and ovarian function.

Stem cell therapy functions through two primary mechanisms: direct differentiation and paracrine signaling. Direct differentiation involves the transformation of transplanted cells into functional endometrial or ovarian cells, whereas paracrine signaling triggers the release of cytokines and growth factors that stimulate the patient's own tissue repair mechanisms [5]. In both processes, stem cells enhance angiogenesis, reduce fibrosis, and promote hormonal balance, leading to improved tissue recovery and function. These mechanisms are particularly valuable in the treatment of gynecologic disorders where the normal regenerative cycle has been disrupted.

Endometrial disorders such as Asherman's syndrome and chronic endometrial atrophy are characterized by fibrosis, adhesion formation, and poor vascularization. In such cases, the normal endometrial regeneration cycle fails, resulting in infertility or recurrent implantation failure. Clinical research has demonstrated that stem cell therapy can effectively reverse these pathological changes in humans. Mesenchymal stem cells introduced into the uterine cavity or through intra-arterial infusion have been shown to restore endometrial structure, improve vascularization, and increase endometrial thickness, leading to successful pregnancies [6]. In a study on infertile women with refractory Asherman's syndrome, the intrauterine administration of autologous bone marrow-derived stem cells resulted in a significant increase in endometrial receptivity and spontaneous conception rates, confirming the regenerative effect of MSCs in humans [7]. Menstrual blood-derived stem cells have also gained attention for their regenerative potential. These cells possess high proliferative capacity and a low risk of immune rejection since they are autologous. In women with thin endometrium resistant to hormonal treatment, transplantation of menstrual blood stem cells has led to measurable increases in endometrial thickness and restored menstrual regularity [8]. Furthermore, combining stem cell therapy with platelet-rich plasma (PRP) has yielded promising results in clinical settings. PRP provides a concentrated source of growth factors such as VEGF, PDGF, and TGF-β, which enhance stem cell activation and promote rapid endometrial repair [9]. Human studies using a combination of autologous bone marrow stem cells and PRP have reported not only histologic improvement of the endometrium but also clinical pregnancies, suggesting the synergistic benefit of this combined regenerative approach [10].

The underlying mechanisms by which stem cells improve endometrial function in humans are multifactorial. These include stimulation of angiogenesis, reduction of fibrosis, modulation of inflammatory responses, and recruitment of native progenitor cells. Additionally, stem cells are believed to influence the local microenvironment through paracrine signaling, releasing growth factors that enhance tissue perfusion and cellular proliferation [11]. The regenerative microenvironment created by stem cells helps restore normal endometrial morphology and function, which is crucial for embryo implantation and successful pregnancy. Ovarian aging and premature ovarian insufficiency represent another major area of stem cell application in human gynecology. Traditionally, ovarian aging was considered irreversible, characterized by depletion of follicles and a decline in estrogen production. However, recent clinical research challenges this notion by demonstrating that stem cell–based interventions can rejuvenate ovarian function. Autologous stem cells introduced directly into the ovarian tissue or via the ovarian artery have been observed to restore hormone production and follicular growth in women diagnosed with POI [12].

In one notable clinical study, women with menopause-onset infertility received intra-ovarian infusions of autologous bone marrow stem cells. Within six months, a significant proportion of patients showed increased serum estrogen levels, decreased follicle-stimulating hormone (FSH) concentrations, and restoration of menstrual cycles. Some participants even achieved natural conception following treatment [13]. Similarly, adipose-derived stem cells and umbilical cord MSCs have shown comparable outcomes in human trials, where improved ovarian blood flow and an increase in antral follicle count were documented. These findings underscore the potential of stem cell therapy not only to delay ovarian aging but also to reverse certain aspects of reproductive senescence. Another innovation gaining recognition in human medicine is dual-double stem cell therapy, which combines mesenchymal and hematopoietic stem cells to maximize ovarian regeneration. This combined approach enhances angiogenesis, reduces inflammation, and supports hormonal normalization. Clinical trials have demonstrated that women treated with dual-double therapy experience increased ovarian volume, restored menstrual cycles, and in some cases, successful pregnancies [14]. These results provide compelling evidence that cellular therapy can reinstate ovarian activity even in women previously considered infertile.

Although clinical success has been encouraging, certain challenges remain before stem cell therapies can become standard reproductive treatments. Ethical considerations regarding stem cell sourcing and use must be strictly addressed, even when using adult or autologous cells. Safety is another major concern, as ensuring the stability and controlled differentiation of transplanted cells is crucial to prevent adverse outcomes such as unwanted tissue formation. Moreover, the lack of standardized clinical protocols and the limited availability of large-scale human studies restrict widespread adoption [10]. Despite these challenges, the growing number of successful clinical outcomes has fueled optimism regarding the integration of stem cell therapy into reproductive health care. In India, regenerative medicine in gynecology has gained significant momentum. Clinical centers have successfully implemented stem cell–based therapies using autologous bone marrow and menstrual blood stem cells for the treatment of refractory endometrial and ovarian disorders. Indian studies have reported improved endometrial thickness, restored menstrual cycles, and spontaneous pregnancies following stem cell transplantation [4]. These advancements not only demonstrate the safety and feasibility of the therapy but also highlight its potential for cost-effective application in resource-limited settings. India's regulatory framework, guided by the Indian Council of Medical Research (ICMR), emphasizes ethical compliance and patient safety while promoting translational clinical research. Globally, the field continues to evolve with the integration of cutting-edge biotechnologies such as 3D bioprinting, cell-free exosome therapy, and gene-edited stem cells. These advancements aim to enhance precision, minimize immune risks, and improve therapeutic efficiency in human reproductive medicine [15]. As more data from human clinical trials accumulate, stem cell–based therapies are poised to redefine treatment strategies for infertility, providing safer, personalized, and biologically integrated alternatives to current modalities. The aim of this paper is to synthesize existing human studies on stem cell applications in gynecology, with emphasis on endometrial regeneration and ovarian rejuvenation. It seeks to outline the key biological mechanisms involved in stem cell–mediated tissue repair, summarize current clinical outcomes, identify existing limitations, and propose future research priorities. Ultimately, the goal is to demonstrate how stem cell therapy offers a transformative strategy for restoring fertility and hormonal balance in women, helping translate experimental advances into practical clinical solutions.

Evolution of Stem Cell Research and Its Relevance in Gynecology

Stem cell research has undergone a significant transformation from basic biological observation to a cornerstone of regenerative medicine. The understanding that stem cells possess the dual ability to self-renew and differentiate into specialized cell types has reshaped how medicine approaches tissue repair and organ regeneration [16]. The historical development of this field can be traced to the discovery of pluripotent and multipotent cells, which initiated the study of embryonic and adult stem cells as sources for therapeutic intervention. Over time, this concept evolved from theoretical models of cellular renewal to experimental applications across various medical disciplines, including gynecology, where regenerative therapy has become a promising alternative for conditions that impair fertility and tissue function [17]. The early stages of stem cell exploration focused on embryonic stem cells derived from blastocysts, highlighting their potential for differentiation into nearly any cell type. However, ethical challenges surrounding embryonic sources led to the emergence of adult stem cells and induced pluripotent stem cells (iPSCs) as viable substitutes. Adult stem cells, particularly mesenchymal stem cells (MSCs), were identified as safer, ethically acceptable, and clinically adaptable. This discovery marked the beginning of translational regenerative medicine, where research moved from laboratory models to clinical studies in humans [18]. In gynecology, this transition played a crucial role in developing therapies for degenerative reproductive conditions, demonstrating that stem cells could restore physiological functions within the endometrium and ovaries.

As regenerative science matured, the focus shifted toward understanding the evolutionary foundation of stem cells and their physiological relevance in human tissues. Stem cells exist in nearly all multicellular organisms, serving as a biological repair system that maintains homeostasis and replaces damaged cells. This universal role underscores the evolutionary conservation of “stemness,” suggesting that regenerative potential has been preserved throughout species evolution as a survival mechanism [19]. In humans, the application of this inherent regenerative ability has opened new therapeutic frontiers in reproductive medicine, allowing damaged tissues such as the uterine lining and ovaries to be revitalized. The capacity of these cells to adapt, proliferate, and respond to environmental cues illustrates their importance in maintaining reproductive health. In gynecology, the integration of stem cell research began with the recognition that the female reproductive system contains intrinsic progenitor cells capable of regeneration. Studies revealed that specific regions, including the endometrial basalis layer and ovarian cortex, harbor adult stem cells with regenerative potential. These findings established a biological foundation for targeted cell-based therapies aimed at conditions such as Asherman’s syndrome, endometrial atrophy, and premature ovarian insufficiency [20]. Over the past two decades, multiple clinical investigations have validated that transplanted autologous or allogeneic stem cells can repair damaged endometrial tissue, improve vascularization, and restore hormonal function, demonstrating that stem cells are not merely laboratory tools but practical regenerative agents in human gynecology.

The progress of stem cell research in reproductive medicine can be divided into three major phases. The first phase involved discovery and classification, where different stem cell types—embryonic, adult, mesenchymal, hematopoietic, and induced pluripotent—were identified and studied for differentiation capacity. The second phase, experimental translation, involved exploring stem cells in tissue cultures and animal models, leading to the establishment of clinical feasibility. The third and ongoing phase, clinical application, focuses on human trials to determine efficacy, safety, and reproducibility in conditions affecting the uterus, ovaries, and pelvic structures. Within this phase, gynecologic regenerative therapy has emerged as a vital area of translational research [21]. Over the years, stem cell research in gynecology has expanded beyond fertility restoration to include cancer biology, hormonal regulation, and tissue repair following surgery or radiotherapy. The role of stem cells in the development and progression of gynecologic malignancies, including ovarian, endometrial, and cervical cancers, has been a focus of ongoing investigation. It is now understood that the deregulation of normal stem cell pathways can lead to cancer stem cell formation, which contributes to tumor recurrence and therapy resistance [22]. Consequently, research into stem cell regulation not only informs regenerative strategies but also provides insights into preventing malignant transformation. The relevance of stem cells in gynecology also lies in their potential for personalized and precision-based medicine. Because stem cells can be harvested from an individual’s own tissues, such as bone marrow, adipose tissue, or menstrual blood, they minimize immune rejection and ethical conflict. This autologous application has enabled the treatment of disorders previously resistant to conventional therapy, particularly where hormonal or surgical interventions fail. In reproductive medicine, autologous stem cell transplantation has shown to improve endometrial receptivity, ovarian reserve, and overall fertility outcomes, redefining the scope of infertility management in clinical practice [23].

Types and Sources of Stem Cells Used in Female Reproductive Regeneration

Stem cell–based regenerative medicine has emerged as one of the most promising fields for the treatment of reproductive disorders. Within the female reproductive system, various stem cell populations have been identified, each possessing unique biological and therapeutic properties that contribute to tissue repair, regeneration, and functional restoration [24]. The human reproductive tract including the uterus, endometrium, myometrium, ovaries, and fallopian tubes contains several stem cell reservoirs. These cells participate in the cyclical regeneration and remodeling processes that occur throughout a woman's reproductive life. Their identification has enabled new strategies for treating infertility, premature ovarian failure, and uterine disorders by leveraging both autologous and allogeneic stem cell sources [25].



Introduction to stem cells. Embryonic stem cells (ESCs) are important for development of a fetus and may be extracted from the inner cell mass of the blastocyst for the purpose of ESC-based therapies. Adult or somatic stem cells (ASCs) reside in the body after birth for the purpose of routine remodeling or repair and regeneration of tissues following injury. While some ASCs retain multilineage potential, the majority are unipotent and differentiation capacity is limited to the tissue type in which they reside. Positive health outcomes associated with exercise, including enhanced repair and improvements in function, may occur as a result of alterations in ASC quantity and/or function in a variety of tissues.

Figure 1: Introduction to stem cells [25]

Stem cells are of two main types: embryonic and adult. Embryonic stem cells are pluripotent but limited in use due to ethical and safety concerns. Adult stem cells, particularly mesenchymal stem cells (MSCs), are multipotent, safer, and widely used in reproductive regeneration [26]. MSCs can differentiate into multiple cell types and secrete factors that promote repair, angiogenesis, and immune regulation. Common MSC sources bone marrow, adipose tissue, umbilical cord, and menstrual blood—differ in accessibility, immunogenicity, and regenerative potential.

Bone marrow–derived mesenchymal stem cells (BM-MSCs), taken from the iliac crest, were the first used in gynecologic regeneration. They restore endometrial thickness, vascularity, and menstrual function, and improve ovarian follicular activity in premature ovarian insufficiency [27]. Adipose-derived stem cells (ADSCs), easily obtained via liposuction, have high yield and paracrine activity, promoting angiogenesis and follicular regeneration. Umbilical cord–derived stem cells (UC-MSCs) and cord blood stem cells (UCB-SCs) are noninvasive, low-immunogenic sources that enhance endometrial receptivity, ovarian function, and angiogenesis through trophic factor secretion [28].

Menstrual blood–derived stem cells (MenSCs) are an innovative and ethical source for reproductive regeneration. Collected noninvasively from menstrual fluid, they have strong proliferation and differentiation abilities similar to mesenchymal stem cells, with excellent immunological compatibility. Their endometrial origin makes them ideal for uterine and ovarian repair, improving endometrial thickness, vascularity, and pregnancy outcomes in clinical use [29]. Endometrial-derived stem cells (EnSCs), located in the basal endometrial layer, naturally drive uterine regeneration. Isolated via biopsy and expanded in vitro, EnSCs can differentiate into stromal, endothelial, and smooth muscle cells, repairing endometrial damage and enhancing implantation. Their multipotent and paracrine properties make them valuable for both autologous and allogeneic therapies, reinforcing their importance in gynecologic regeneration [30].

Mechanisms of Stem Cell Action in Gynecologic Regeneration

The regenerative potential of stem cells in gynecology arises from their unique biological mechanisms that promote tissue repair, restore hormonal balance, and reverse degenerative changes in the female reproductive system. These mechanisms include direct cellular differentiation, paracrine signaling, immunomodulation, angiogenesis, anti-fibrotic activity, and extracellular vesicle-mediated communication. Understanding these underlying processes has been instrumental in translating stem cell research from laboratory studies to clinical therapies targeting endometrial and ovarian regeneration [31]. The first fundamental mechanism is cellular differentiation, through which stem cells transform into functional tissue-specific cells. In gynecologic regeneration, stem cells have demonstrated the ability to differentiate into endometrial epithelial, stromal, vascular endothelial, and granulosa-like cells when exposed to the appropriate hormonal and molecular environment. For example, transplanted mesenchymal stem cells (MSCs) in the uterus or ovary can integrate with native tissue and replace damaged or senescent cells, thereby re-establishing normal tissue architecture. Differentiation is guided by molecular signaling pathways such as Wnt, Notch, TGF-β, and PI3K/Akt, which regulate stem cell fate and proliferation. These pathways coordinate the conversion of stem cells into mature cell types necessary for the restoration of uterine and ovarian functions [32]. Paracrine signaling is a key mechanism in stem cell–based regeneration, where stem cells secrete growth factors and cytokines that stimulate tissue repair, angiogenesis, and reduce inflammation. Factors like VEGF, bFGF, HGF, and IGF-1 activate dormant uterine and ovarian progenitor cells, restoring endometrial and follicular function [33]. Linked to this is exosomal communication, in which stem cells release vesicles carrying proteins and microRNAs that mimic cell functions without transplantation. These exosomes reduce oxidative stress, promote angiogenesis, and modulate inflammation, offering a safer, cell-free therapeutic alternative for gynecologic regeneration [34].

Immunomodulation is a crucial mechanism by which stem cells regulate inflammation and create a favorable environment for tissue repair. In gynecologic disorders like endometrial atrophy and premature ovarian insufficiency, chronic inflammation drives degeneration. Stem cells secrete IL-6, IL-10, PGE2, and TSG-6, which suppress pro-inflammatory cytokines, reduce immune cell activation, and prevent rejection of transplanted cells. This helps limit tissue damage and supports follicular protection, restoring normal hormonal and ovulatory function [35]. Angiogenesis, another vital mechanism, enhances blood flow to regenerating tissues. Stem cells either differentiate into endothelial-like cells or release VEGF and angiopoietin, stimulating vascular growth. Improved perfusion supplies oxygen and nutrients essential for regeneration in the endometrium and ovaries, increasing receptivity, implantation success, and ovarian activity [36]. Stem cells also reduce fibrosis and apoptosis, ensuring sustained recovery. By regulating MMPs and TIMPs, they prevent excessive extracellular matrix deposition, reducing uterine scarring. Anti-apoptotic proteins like Bcl-2 and survivin preserve surrounding cells, maintaining tissue integrity. In ovarian tissue, these effects prevent granulosa cell loss, extend follicle life, and promote hormonal stability [37].

Stem Cell Applications in Endometrial Regeneration

The human endometrium is a dynamic and regenerative tissue that undergoes more than four hundred cycles of shedding, repair, and regrowth throughout a woman's reproductive lifespan. Its ability to regenerate rapidly after each menstrual cycle is primarily attributed to the presence of resident and migratory stem cell populations that maintain its structure and function. When the normal regenerative process is disrupted by trauma, infection, or surgical interventions, it may lead to conditions such as Asherman's syndrome, endometrial atrophy, and infertility. Stem cell therapy has emerged as a promising intervention capable of restoring the damaged endometrial environment and reestablishing fertility through structural and functional regeneration [38]. Endometrial regeneration is orchestrated by a diverse population of stem and progenitor cells located within the basal layer of the endometrium. These include mesenchymal-like stem cells, epithelial progenitor cells, endothelial progenitor cells, and perivascular cells. These resident stem cells possess the ability to self-renew and differentiate into epithelial, stromal, and vascular cell lineages. When transplanted or stimulated, they can repair injured tissue and reconstitute the multilayered structure of the endometrium. Research on human subjects has confirmed that these cells play a vital role in the regeneration of endometrial tissue following trauma or pathological thinning. The identification of endometrial mesenchymal stem cells expressing CD146 and PDGF-Rβ markers provided a breakthrough in understanding their contribution to physiological endometrial regeneration and their potential for therapeutic use in cases of endometrial failure [39].



Mechanisms of stem cell therapy in endometrial regeneration. Stem cell therapy promotes endometrial regeneration through two primary mechanisms: cellular differentiation and paracrine activity. Transplanted stem cells can directly differentiate into endometrial progenitor/stem cells and exert paracrine effects that facilitate immunomodulation, angiogenesis, and activation of resident stem cells. These actions collectively improve the endometrial microenvironment, thereby supporting tissue regeneration, repair, and cellular proliferation. Abbreviation: HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor-1; VEGF, vascular endothelial growth factor; HLA-G, human leukocyte antigen-G; PGE2, prostaglandin E2. .

Figure 2: Mechanisms of stem cell therapy in endometrial regeneration [39]

In clinical applications, various sources of stem cells have been investigated for endometrial repair, including bone marrow–derived stem cells (BMDSCs), adipose-derived mesenchymal stem cells (ADSCs), and umbilical cord–derived mesenchymal stem cells (UC-MSCs). These exogenous cells exhibit remarkable plasticity and can differentiate into endometrial cell types or secrete trophic factors that stimulate endogenous repair mechanisms. Among these, BMDSCs have received the most attention due to their demonstrated ability to migrate naturally to the uterus and participate in tissue regeneration. Human clinical studies have shown that intrauterine infusion of autologous BMDSCs can restore menstrual function, increase endometrial thickness, and lead to successful pregnancies in women with Asherman's syndrome or endometrial atrophy. These findings established bone marrow stem cells as a key therapeutic option in regenerative gynecology [40]. Adipose-derived stem cells have also been successfully applied for endometrial regeneration. These cells possess high proliferative capacity, strong immunomodulatory properties, and the ability to secrete angiogenic factors such as VEGF and bFGF. Their ease of extraction through minimally invasive procedures and high cell yield make them ideal for autologous transplantation. In cases of severe endometrial fibrosis, adipose-derived stem cell therapy combined with biomaterial scaffolds has demonstrated enhanced regeneration by improving vascularization, reducing scar tissue formation, and restoring glandular structure. Recent developments in scaffold-based delivery systems have further improved stem cell retention and survival, maximizing their reparative impact on the uterine environment [41].

Umbilical cord–derived mesenchymal stem cells, obtained noninvasively from postpartum tissues, offer an ethically acceptable and immunologically compatible alternative to adult stem cells. Clinical evidence indicates that UC-MSCs enhance endometrial regeneration by promoting epithelial proliferation, stimulating angiogenesis, and inhibiting fibrosis. They release extracellular vesicles and cytokines that activate resident progenitor cells and improve uterine receptivity. In some clinical trials, UC-MSC transplantation resulted in the resumption of menstruation and successful pregnancies in women with severe intrauterine adhesions. Their low immunogenicity and potent paracrine effects make UC-MSCs a favorable option for allogeneic stem cell therapy in reproductive medicine [42]. Menstrual blood–derived stem cells, sometimes referred to as endometrial regenerative cells, represent one of the most innovative autologous sources for uterine regeneration. These cells are derived from the functional layer of the endometrium and retain mesenchymal stem cell characteristics, including high proliferation and multipotency. Because menstrual blood collection is simple, noninvasive, and repeatable, MenSCs present a practical and ethical alternative for regenerative applications. Human studies have shown that transplantation of MenSCs into the uterine cavity leads to significant improvements in endometrial thickness, enhanced vascularization, and better receptivity for implantation. Their biological compatibility and ability to secrete regenerative factors such as IGF, HGF, and IL-10 underscore their effectiveness in restoring uterine function [43]. The mechanisms through which stem cells restore endometrial tissue are multifaceted. They contribute through differentiation into stromal, glandular, and endothelial cells, as well as via paracrine signaling that recruits resident progenitor cells and promotes angiogenesis. Additionally, they suppress inflammation, reduce oxidative stress, and modulate the immune response, creating an environment conducive to healing. In particular, the paracrine secretion of growth factors like VEGF, EGF, and TGF-β plays a crucial role in re-establishing endometrial vascular networks and preventing fibrotic scarring. This paracrine effect has been demonstrated to be equally, if not more, important than direct cellular integration in achieving successful endometrial repair [44].

Stem Cell Applications in Ovarian Rejuvenation

Ovarian rejuvenation through stem cell therapy has emerged as one of the most promising advancements in reproductive medicine, particularly for women experiencing premature ovarian insufficiency (POI), diminished ovarian reserve (DOR), or age-related infertility. The traditional concept that women are born with a finite number of oocytes has been challenged by discoveries showing that residual primordial follicles and ovarian stem cells may persist into adulthood, capable of being reactivated under appropriate conditions. Stem cell–based approaches aim to restore ovarian function, enhance folliculogenesis, and improve endocrine balance, offering new hope for women who have exhausted conventional fertility treatments [45]. The biological foundation of ovarian rejuvenation lies in the presence of small populations of progenitor or stem-like cells within the ovarian cortex, capable of self-renewal and differentiation. These ovarian stem cells are believed to contribute to oogenesis and follicular renewal when stimulated by specific growth factors or cellular environments. In addition to endogenous cells, transplanted stem cells—such as bone marrow–derived, adipose-derived, or umbilical cord–derived mesenchymal stem cells—can exert reparative effects either by direct differentiation or through the secretion of paracrine factors that promote tissue repair and angiogenesis. These processes collectively enhance the microenvironment of the ovary, facilitating the maturation of dormant follicles and the recovery of hormonal activity [46].

Clinical and preclinical research has demonstrated that autologous bone marrow–derived stem cells (BMDSCs) play a crucial role in improving ovarian function. When injected intra-ovarianly, BMDSCs have been observed to enhance follicular activation, stimulate angiogenesis, and restore levels of anti-Müllerian hormone (AMH), estradiol, and follicle-stimulating hormone (FSH). The paracrine release of cytokines such as VEGF and IGF-1 supports local vascularization and prevents apoptosis of granulosa cells. Several women with POI or diminished ovarian reserve have resumed menstruation and even achieved pregnancy following bone marrow stem cell therapy. These outcomes suggest that BMDSCs can rejuvenate residual follicles by creating an environment favorable for folliculogenesis [47]. Adipose-derived mesenchymal stem cells (ADSCs) have also gained attention due to their accessibility, high yield, and potent regenerative capacity. In human clinical trials, ADSCs are typically harvested via liposuction and infused directly into the ovarian stroma under ultrasound guidance. Their anti-inflammatory and pro-angiogenic properties help restore endocrine function and ovarian morphology. ADSC therapy has shown measurable improvement in AMH levels and follicular count, particularly in women with poor ovarian response undergoing in vitro fertilization. Furthermore, adipose-derived stromal vascular fraction containing ADSCs has demonstrated safety and partial restoration of ovarian responsiveness in phase I clinical studies, reinforcing its therapeutic viability [48].

Another innovative approach involves umbilical cord–derived mesenchymal stem cells (UC-MSCs) and placenta-derived stem cells, which have strong proliferative potential and immunomodulatory capacity. These allogeneic cells can secrete multiple trophic factors that enhance follicle survival, angiogenesis, and hormonal regulation. UC-MSC therapy has shown promise in restoring estrous cycles and improving ovarian histology in human and experimental models of ovarian failure. The anti-apoptotic and metabolic regulatory properties of these cells help rejuvenate ovarian tissue and mitigate oxidative stress, which contributes to oocyte depletion during aging. Moreover, placenta-derived stem cells have been found to modify systemic metabolism, increase circulating levels of insulin-like growth factor-1, and stimulate mitochondrial biogenesis, all of which enhance ovarian vitality [49]. A key mechanism underlying ovarian rejuvenation is the activation of dormant primordial follicles through molecular signaling pathways such as PI3K/Akt, Hippo, and mTOR. Stem cells, when transplanted into the ovary, can disrupt inhibitory signals within the ovarian cortex and promote the recruitment of quiescent follicles into active growth. This process is often complemented by the use of platelet-rich plasma (PRP), which contains high concentrations of cytokines and growth factors that further stimulate stem cell activity and tissue regeneration. The combined use of stem cells and PRP has been shown to restore ovulatory function and improve ovarian reserve parameters in women with POI [50].

In addition to cellular therapies, the discovery of oogonial stem cells (OSCs) in the human ovary has revolutionized understanding of reproductive aging. These small, pluripotent cells are capable of differentiating into oocyte-like cells under favorable conditions. Stimulation or transplantation of OSCs may enable the formation of new follicles, providing a biological basis for neo-oogenesis in adult women. Although the existence and functionality of OSCs remain subjects of debate, their potential application represents a paradigm shift in reproductive medicine. Ovarian tissue reactivation using OSCs, in combination with autologous growth factors or stem cells, has already demonstrated improvement in hormonal profiles and ovarian morphology [51]. The clinical success of stem cell–based ovarian rejuvenation is assessed through measurable parameters such as AMH, FSH, estradiol levels, antral follicle count, and the return of menstrual cycles. Reported improvements in these indicators following stem cell or PRP therapy suggest partial restoration of ovarian function and enhanced response to assisted reproduction techniques. While the majority of clinical studies have involved small sample sizes, the results are consistently encouraging, showing increased ovarian volume, follicular activity, and pregnancy rates among treated women. Importantly, no significant adverse effects or tumorigenic outcomes have been observed, supporting the safety profile of autologous stem cell interventions [52]. Stem cell applications in ovarian rejuvenation offer a groundbreaking approach to reversing age- or disease-related ovarian decline. Through mechanisms involving angiogenesis, immunomodulation, paracrine signaling, and follicular activation, stem cells restore both reproductive and endocrine ovarian function. Although large-scale randomized trials are still needed, current human evidence underscores the therapeutic potential of bone marrow, adipose, umbilical cord, and ovarian stem cells in improving fertility outcomes. This evolving field not only holds implications for infertility management but also represents a significant step toward delaying ovarian aging and enhancing women's reproductive health [52].

Comparative Evaluation of Stem Cell Sources and Clinical Outcomes

The use of stem cells in reproductive regeneration has expanded rapidly, leading to the development of multiple therapeutic strategies targeting ovarian and endometrial repair. Various stem cell sources, including bone marrow, adipose tissue, menstrual blood, umbilical cord, and endometrial tissue, have been tested for their regenerative efficacy and clinical safety. Comparative evaluation of these sources highlights distinct biological properties, regenerative capacities, and clinical outcomes that determine their suitability for specific gynecologic applications [53]. Bone marrow–derived stem cells (BMDSCs) are among the most extensively investigated and clinically validated stem cell types in reproductive medicine. They possess multipotent differentiation potential and a well-characterized immunomodulatory profile. Clinical outcomes with BMDSCs have consistently demonstrated improvement in endometrial thickness, angiogenesis, and hormonal balance in women with Asherman's syndrome or thin endometrium. Similarly, intra-ovarian infusion of autologous BMDSCs has resulted in the recovery of follicular function and the resumption of menses in women with premature ovarian insufficiency. However, bone marrow aspiration is an invasive procedure, and the yield of mesenchymal cells is relatively low compared to other sources. Despite this, BMDSCs remain a preferred choice for autologous applications due to their proven clinical efficacy and safety profile [54].

Adipose-derived mesenchymal stem cells (ADSCs) offer a less invasive and more accessible alternative. They are abundant, easy to harvest via liposuction, and exhibit high proliferative potential. ADSCs secrete potent paracrine factors such as VEGF and HGF that promote angiogenesis and tissue remodeling, which enhances their therapeutic effect. Clinical reports indicate that ADSC transplantation improves endometrial vascularization, reduces fibrosis, and increases receptivity to embryo implantation. In ovarian rejuvenation, ADSC therapy has improved ovarian reserve markers and follicular response. The principal advantages of ADSCs include high cell yield, minimal donor morbidity, and robust anti-inflammatory action. Nevertheless, the variability in donor adipose tissue quality and differences in culture protocols may influence therapeutic outcomes [55]. Umbilical cord–derived mesenchymal stem cells (UC-MSCs) represent a promising allogeneic source with strong regenerative and immunomodulatory properties. These cells are derived noninvasively from postpartum tissues and exhibit low immunogenicity, allowing their use across different patients without immune rejection. UC-MSCs have been applied in women with severe intrauterine adhesions and ovarian insufficiency, where they demonstrated improved endometrial regeneration, revascularization, and restoration of ovarian steroidogenesis. Compared with adult stem cells, UC-MSCs proliferate faster, have greater resistance to senescence, and maintain higher secretory activity. Their clinical outcomes are encouraging, with observed increases in endometrial thickness, improved menstrual regularity, and higher conception rates. The main challenges are the need for standardized isolation techniques and long-term safety validation for large-scale use [56]. Menstrual blood–derived stem cells (MenSCs) provide an innovative, autologous, and ethically acceptable stem cell source. These cells are isolated from menstrual fluid and retain characteristics similar to mesenchymal stem cells. They are particularly suited for endometrial repair because of their inherent origin from the uterine lining. In clinical applications, intrauterine transplantation of MenSCs has resulted in significant improvements in endometrial structure and function, including the formation of new glands and restoration of normal menstrual flow. Patients with thin endometrium who were unresponsive to hormonal therapy achieved improved pregnancy rates after MenSC therapy. The noninvasive collection method and absence of ethical concerns make MenSCs an ideal candidate for repeated treatments. However, the relative scarcity of large-scale clinical studies necessitates further investigation to confirm reproducibility and long-term outcomes [57].

Endometrial-derived stem cells (EnSCs), sourced directly from endometrial tissue biopsies, are another viable autologous option. EnSCs are naturally involved in cyclical endometrial regeneration and can differentiate into stromal, epithelial, and endothelial cells. Clinical trials utilizing EnSCs for endometrial injury repair have reported restoration of glandular morphology and reduced fibrosis, confirming their potential for targeted uterine regeneration. The principal benefit of EnSCs lies in their physiological relevance and responsiveness to reproductive hormones. However, their limited availability from patients with severe endometrial scarring and the requirement for invasive biopsy procedures restrict widespread use [58]. Comparative evaluations indicate that bone marrow and umbilical cord–derived stem cells offer superior angiogenic and immunomodulatory benefits, making them more effective for severe endometrial and ovarian pathologies. In contrast, adipose and menstrual blood stem cells provide accessible autologous sources that are better suited for personalized treatment due to lower procedural risk. Endometrial stem cells, while optimal for local regeneration, are restricted by tissue availability. Clinical outcome measures such as endometrial thickness, AMH levels, and pregnancy rates show consistent improvement across all cell sources, though the degree of efficacy varies according to the type and delivery route of stem cells used. Emerging meta-analyses suggest that combining stem cells with scaffolds or platelet-rich plasma further enhances regeneration by increasing cell retention and paracrine factor delivery [59].

Ethical, Technical, and Clinical Challenges in Human Stem Cell Therapy

The translation of stem cell research from experimental models to human reproductive medicine presents a range of ethical, technical, and clinical challenges that must be addressed to ensure the safety, efficacy, and societal acceptance of these therapies. The ethical issues primarily arise from the source of stem cells, patient consent, and potential misuse of unproven treatments. While embryonic stem cells once held promise due to their pluripotency, their use has been largely restricted because of moral objections related to embryo destruction. As a result, focus has shifted toward adult and perinatal stem cells, which are ethically acceptable and clinically viable. However, even within permissible sources, there remain concerns about commercialization, patient exploitation, and the offering of unregulated stem cell therapies without adequate clinical validation [60]. -Technical challenges also limit the large-scale application of stem cell therapy in gynecology. These include difficulties in stem cell isolation, culture standardization, and ensuring long-term stability and genetic integrity. Maintaining stem cell purity and preventing spontaneous differentiation or tumorigenic transformation are crucial for clinical safety [61]. Additionally, the delivery route, dosage, and timing of stem cell administration require optimization to maximize therapeutic outcomes. The use of biomaterials and scaffolds to enhance cell retention and survival introduces further complexity in regulatory approval and quality control. Variability among cell donors and differences in laboratory techniques can also lead to inconsistent results, posing significant barriers to reproducibility and standardization [62].

Clinically, challenges include the lack of large-scale randomized trials, limited long-term safety data, and uncertainties surrounding immune compatibility in allogeneic therapies. While short-term studies report favorable outcomes in endometrial and ovarian regeneration, the absence of extended follow-up raises questions about potential adverse effects such as fibrosis, ectopic tissue formation, or neoplasia [63]. Establishing comprehensive guidelines for patient selection, informed consent, and post-therapy monitoring is critical to ensure ethical compliance and patient protection. Regulatory frameworks—such as those enforced by the Indian Council of Medical Research and global health authorities—play a vital role in maintaining clinical integrity while fostering innovation. Overcoming these ethical, technical, and clinical barriers is essential for transforming stem cell therapy from an experimental approach to a standardized, safe, and ethically sound component of reproductive medicine [64].

Table 1: Future Perspectives and Research Gaps in Regenerative Gynecology

Key Focus Area	**Summary of Insights**	**References**
Stem cell therapy as a transformative approach in regenerative gynecology	Stem cell therapy offers new potential for restoring fertility and reproductive function, but requires standardization, optimization, and long-term validation for clinical reliability.	[65]
Integration of gene editing (CRISPR-Cas9) and molecular modulation	Gene editing and RNA modulation can enhance stem cell differentiation, increase survival, and improve safety, enabling targeted regeneration of ovarian and endometrial tissues.	[66]
Advances in biomaterials and 3D bioprinting for reproductive tissue reconstruction	3D bioprinting and biomaterials create customized scaffolds that support uterine and ovarian tissue regeneration and integration with native structures.	[67]
Development of cell-free therapies (exosomes and secretomes)	Exosome-based therapies reproduce many regenerative effects of stem cells without ethical or immune concerns, offering safer and scalable alternatives for clinical use.	[68]
Challenges: small sample sizes, lack of standardized protocols, limited long-term studies	Research is limited by small cohorts, short follow-ups, and inconsistent methods for stem cell isolation, dosing, and administration across clinical studies.	[69]
Need for addressing socioeconomic and regulatory issues	There is an urgent need to improve access, ensure equity, and strengthen ethical regulations to prevent misuse and commercialization of unverified stem cell treatments.	[70]

Conclusion

Stem cell therapy represents a paradigm shift in the management of female reproductive disorders by enabling the regeneration of endometrial and ovarian tissues. The clinical use of mesenchymal and endometrial-derived stem cells has demonstrated significant improvements in fertility outcomes, endometrial receptivity, and ovarian function. However, major challenges remain, including the need for standardized stem cell isolation methods, optimal dosing, delivery techniques, and long-term follow-up to confirm safety and efficacy. Ethical considerations and regulatory oversight must ensure that clinical applications remain evidence-based and patient-centered. Future research should focus on integrating gene editing, biomaterials, and exosome technology to enhance therapeutic precision and minimize risk. Multidisciplinary collaboration among clinicians, bioengineers, and molecular scientists will be critical in advancing regenerative gynecology from experimental therapy to clinical reality. With continued innovation and ethical responsibility, stem cell–based regeneration holds immense potential to redefine fertility restoration, delay reproductive aging, and improve women's reproductive health worldwide.

REFERENCES

1. Nair S, Agarwal A. Stem cell treatments for female reproductive disorders: a comprehensive review. J Ovarian Res. 2025;18:1–10. doi:10.1186/s13048-025-01750-y.
2. Ivkošić I, Fureš R, Ćosić V, Mikelin N, Bulić L, Dobranić D, Brlek P, Primorac D. Unlocking the potential of mesenchymal stem cells in gynecology: where are we now? J Pers Med. 2023;13(8):1253. doi:10.3390/jpm13081253.
3. Lv Q, Wang L, Luo X, Chen X. Adult stem cells in endometrial regeneration: molecular insights and clinical applications. Mol Reprod Dev. 2021;88(5):379–394. doi:10.1002/mrd.23476.
4. Anagani M, Agrawal P, Reddy BV, Mishra P. Role of autologous bone marrow-derived stem cells and platelet rich plasma for endometrial regeneration and repair and ovarian rejuvenation. Int J Reprod Contracept Obstet Gynecol. 2021;10(2):597–602. doi:10.18203/2320-1770.IJRCOG20210311.
5. Li S, Ding L. Endometrial perivascular progenitor cells and uterus regeneration. J Pers Med. 2021;11(6):477. doi:10.3390/jpm11060477.
6. Strug M, Aghajanova L. Making more womb: clinical perspectives supporting the development and utilization of mesenchymal stem cell therapy for endometrial regeneration and infertility. J Pers Med. 2021;11(12):1364. doi:10.3390/jpm11121364.
7. Tinjić S, Abazović D, Ljubić D, Vujović S, Vojvodić D, Božanović T, Ljubić A. Ovarian rejuvenation. Donald Sch J Ultrasound Obstet Gynecol. 2019;13(3):152–160. doi:10.5005/jp-journals-10009-1587.
8. Lee YJ, Yi K. Bone marrow-derived stem cells contribute to regeneration of the endometrium. Clin Exp Reprod Med. 2018;45(4):149–153. doi:10.5653/cerm.2018.45.4.149.
9. Ferrari AR, Cortrezzi S, Borges Júnior E, Braga D, de Souza MD, Antunes R. Evaluation of the effects of platelet-rich plasma on follicular and endometrial growth: a literature review. JBRA Assist Reprod. 2021;25(4):601–607. doi:10.5935/1518-0557.20210036.
10. Cai Y, Wang S, Qu J, Belmonte JCI, Liu GH. Rejuvenation of tissue stem cells by intrinsic and extrinsic factors. Stem Cells Transl Med. 2022;11(3):231–238. doi:10.1093/stcltm/szab012.
11. Park SR, Kim SK, Kim SR, Park JR, Lim S, Hong I. Novel roles of luteinizing hormone in tissue regeneration-associated functions in endometrial stem cells. Cell Death Dis. 2022;13(1):40–50. doi:10.1038/s41419-022-05054-7.
12. Mutlu L, Hufnagel D, Taylor HS. The endometrium as a source of mesenchymal stem cells for regenerative medicine. Biol Reprod. 2015;92(6):134–142. doi:10.1095/biolreprod.114.126771.
13. Ljubić A, Dinić M, Švraka D, Vujović S. Dual-double stem cell ovarian therapy: a comprehensive approach in regenerative medicine. Int J Mol Sci. 2024;26(1):69. doi:10.3390/ijms26010069.
14. Du H, Taylor HS. Stem cells and reproduction. Curr Opin Obstet Gynecol. 2010;22(4):235–241. doi:10.1097/GCO.0b013e328338c152.
15. Gargett CE, Masuda H. Adult stem cells in the endometrium. Molecular human reproduction. 2010 Nov 1;16(11):818-34.
16. Duke CM, Taylor HS. Stem cells and the reproductive system: historical perspective and future directions. Maturitas. 2013 Nov 1;76(3):284-9.
17. Bongso A, Richards M. History and perspective of stem cell research. Best practice & research Clinical obstetrics & gynaecology. 2004 Dec 1;18(6):827-42.
18. Lane FL, Jacobs S. Stem cells in gynecology. American journal of obstetrics and gynecology. 2012 Sep 1;207(3):149-56.
19. Gargett CE. Stem cells in gynaecology. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2004 Oct;44(5):380-6.
20. Gao Y, Wu G, Xu Y, Zhao D, Zheng L. Stem cell-based therapy for asherman syndrome: promises and challenges. Cell Transplantation. 2021 Jun 8;30:09636897211020734.
21. Du H, Taylor HS. Reviews: stem cells and female reproduction. Reproductive Sciences. 2009 Feb;16(2):126-39.
22. Ratajczak MZ, Jadczyk T, Pedziwiatr D, Wojakowski W. New advances in stem cell research: practical implications for regenerative medicine. Pol Arch Med Wewn. 2014 Jan 1;124(7-8):417-26.
23. Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. Stem cell research

& therapy. 2019 Feb 26;10(1):68.
24. Khanlarkhani N, Baazm M, Mohammadzadeh F, Najafi A, Mehdinejadiani S, Sobhani A. Multipotent Stem Cell and Reproduction. Journal of stem cells. 2016 Oct 1;11(4).
25. Boppart, Marni & De Lisio, Michael & Witkowski, Sarah. (2015). Exercise and Stem Cells. Progress in Molecular Biology and Translational Science. 135. 10.1016/bs.pmbts.2015.07.005.
26. Hipp J, Atala A. Sources of stem cells for regenerative medicine. Stem cell reviews. 2008 Mar;4(1):3-11.
27. Zhao YX, Chen SR, Su PP, Huang FH, Shi YC, Shi QY, Lin S. Using mesenchymal stem cells to treat female infertility: an update on female reproductive diseases. Stem cells international. 2019;2019(1):9071720.
28. Ono M, Maruyama T, Yoshimura Y. Regeneration and adult stem cells in the human female reproductive tract. Stem Cells and Cloning: Advances and Applications. 2008 Dec 2:23-9.
29. Fazeli Z, Abedindo A, Omrani MD, Ghaderian SM. Mesenchymal stem cells (MSCs) therapy for recovery of fertility: a systematic review. Stem cell reviews and reports. 2018 Feb;14(1):1-2.
30. Naeem A, Gupta N, Naeem U, Elrayess MA, Albanese C. Amniotic stem cells as a source of regenerative medicine to treat female infertility. Human Cell. 2023 Jan;36(1):15-25.
31. Xu Y, Zhu H, Zhao D, Tan J. Endometrial stem cells: clinical application and pathological roles. International journal of clinical and experimental medicine. 2015 Dec 15;8(12):22039.
32. Sadiasa A, Werkmeister JA, Gurung S, Gargett CE. Steps towards the clinical application of endometrial and menstrual fluid mesenchymal stem cells for the treatment of gynecological disorders. Expert Opinion on Biological Therapy. 2025 Mar 4;25(3):285-307.
33. Erceg Ivkošić I, Fureš R, Ćosić V, Mikelin N, Bulić L, Dobranić D, Brlek P, Primorac D. Unlocking the potential of mesenchymal stem cells in gynecology: where are we now?. Journal of personalized medicine. 2023 Aug 13;13(8):1253.
34. de Miguel-Gomez L, Ferrero H, Lopez-Martinez S, Campo H, Lopez-Perez N, Faus A, Hervás D, Santamaría X, Pellicer A, Cervelló I. Stem cell paracrine actions in tissue regeneration and potential therapeutic effect in human endometrium: a retrospective study. BJOG: an International Journal of Obstetrics & Gynaecology. 2020 Apr;127(5):551-60.
35. Coulson-Thomas VJ, Coulson-Thomas YM, Gesteira TF, Kao WW. Extrinsic and intrinsic mechanisms by which mesenchymal stem cells suppress the immune system. The ocular surface. 2016 Apr 1;14(2):121-34.
36. Gargett CE, Chan RW, Schwab KE. Hormone and growth factor signaling in endometrial renewal: role of stem/progenitor cells. Molecular and cellular endocrinology. 2008 Jun 25;288(1-2):22-9.
37. Taherian M, Bayati P, Mojtabavi N. Stem cell-based therapy for fibrotic diseases: mechanisms and pathways. Stem cell research & therapy. 2024 Jun 18;15(1):170.
38. Zhu X, Péault B, Yan G, Sun H, Hu Y, Ding L. Stem cells and endometrial regeneration: from basic research to clinical trial. Current Stem Cell Research & Therapy. 2019 May 1;14(4):293-304.
39. Chen, Hsuan-Ju & Chang, Hsun-Ming. (2025). Stem Cell-Based Therapies for Refractory Thin Endometrium in In vitro Fertilization: Advances, Challenges, and Future Prospects. 10.5772/intechopen.1011925.
40. Santamaria X, Mas A, Cervelló I, Taylor H, Simon C. Uterine stem cells: from basic research to advanced cell therapies. Human Reproduction Update. 2018 Nov 1;24(6):673-93.
41. Verdi J, Tan A, Shoae-Hassani A, Seifalian AM. Endometrial stem cells in regenerative medicine. Journal of Biological Engineering. 2014 Aug 1;8(1):20.
42. Gargett CE, Ye L. Endometrial reconstruction from stem cells. Fertility and sterility. 2012 Jul 1;98(1):11-20.
43. Azizi R, Aghebati-Maleki L, Nouri M, Marofi F, Negargar S, Yousefi M. Stem cell therapy in Asherman syndrome and thin endometrium: Stem cell-based therapy. Biomedicine & Pharmacotherapy. 2018 Jun 1;102:333-43.
44. Zuo W, Xie B, Li C, Yan Y, Zhang Y, Liu W, Huang J, Chen D. The clinical applications of endometrial mesenchymal stem cells. Biopreservation and Biobanking. 2018 Apr 1;16(2):158-64.
45. Zolbin MM, Aliakbari F, Mehdinejadiani S, Dayabari SS, Shojaie L, Haider KH, Johnson J. Ovarian stem cells and progenitors and their regenerative capabilities. InStem cells: from potential to promise 2021 Sep 25 (pp. 83-106). Singapore: Springer Singapore.
46. Cui X, Jing X. Stem cell-based therapeutic potential in female ovarian aging and infertility. Journal of Ovarian Research. 2024 Aug 24;17(1):171.
47. Tandulwadkar S, Karthick MS. Combined use of autologous bone marrow-derived stem cells and platelet-rich plasma for ovarian rejuvenation in poor responders. Journal of human reproductive sciences. 2020 Jul 1;13(3):184-90.
48. Museridze N, Chokhonelidze A. Advances in Stem Cell Therapy for Reproductive Medicine: Applications, Techniques, and Potential Outcomes. Medical Times. 2024 Oct 14;2(1):42-9.
49. Lorzadeh N, Kazemirad N. Application of stem cells to infertility treatment with emphasis on mesenchymal stem cells and ovarian stem cells. American journal of perinatology. 2018 Oct;35(12):1142-7.
50. Akahori T, Woods DC, Tilly JL. Female fertility preservation through stem cell-based ovarian tissue reconstitution in vitro and ovarian regeneration in vivo. Clinical Medicine Insights: Reproductive Health. 2019 May;13:1179558119848007.
51. Yuan Z, Zhang Y, He X, Wang X, Wang X, Ren S, Su J, Shen J, Li X, Xiao Z. Engineering mesenchymal stem

cells for premature ovarian failure: Overcoming challenges and innovating therapeutic strategies. Theranostics. 2024 Oct 7;14(17):6487.

52. Gupta S, Lodha P, Karthick MS, Tandulwadkar SR. Role of autologous bone marrow-derived stem cell therapy for follicular recruitment in premature ovarian insufficiency: review of literature and a case report of world's first baby with ovarian autologous stem cell therapy in a perimenopausal woman of age 45 year. Journal of human reproductive sciences. 2018 Apr 1;11(2):125-30.

53. Herraiz S, Buigues A, Díaz-García C, Romeu M, Martínez S, Gómez-Seguí I, Simón C, Hsueh AJ, Pellicer A. Fertility rescue and ovarian follicle growth promotion by bone marrow stem cell infusion. Fertility and sterility. 2018 May 1;109(5):908-18.

54. Vassena R, Eguizabal C, Heindryckx B, Sermon K, Simon C, van Pelt AM, Veiga A, Zambelli F. Stem cells in reproductive medicine: ready for the patient?. Human Reproduction. 2015 Sep 1;30(9):2014-21.

55. Benor A, Gay S, DeCherney A. An update on stem cell therapy for Asherman syndrome. Journal of Assisted Reproduction and Genetics. 2020 Jul;37(7):1511-29.

56. Mazini L, Rochette L, Amine M, Malka G. Regenerative capacity of adipose derived stem cells (ADSCs), comparison with mesenchymal stem cells (MSCs). International journal of molecular sciences. 2019 May 22;20(10):2523.

57. Qin Y, Ge G, Yang P, Wang L, Qiao Y, Pan G, Yang H, Bai J, Cui W, Geng D. An update on adipose-derived stem cells for regenerative medicine: where challenge meets opportunity. Advanced Science. 2023 Jul;10(20):2207334.

58. Chen L, Qu J, Cheng T, Chen X, Xiang C. Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases. Stem cell research & therapy. 2019 Dec 21;10(1):406.

59. Cousins FL, Filby CE, Gargett CE. Endometrial stem/progenitor cells–their role in endometrial repair and regeneration. Frontiers in reproductive health. 2022 Jan 20;3:811537.

60. Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, Armstrong L, Djonov V, Lako M, Stojkovic M. Ethical and safety issues of stem cell-based therapy. International journal of medical sciences. 2018 Jan 1;15(1):36.

61. King NM, Perrin J. Ethical issues in stem cell research and therapy. Stem cell research & therapy. 2014 Jul 7;5(4):85.

62. Park SJ, Kim YY, Han JY, Kim SW, Kim H, Ku SY. Advancements in human embryonic stem cell research: clinical applications and ethical issues. Tissue Engineering and Regenerative Medicine. 2024 Apr;21(3):379-94.

63. Lukomska B, Stanaszek L, Zuba-Surma E, Legosz P, Sarzynska S, Drela K. Challenges and controversies in human mesenchymal stem cell therapy. Stem cells international. 2019;2019(1):9628536.

64. Khandia R, Gurjar P, Romashchenko V, Al-Hussain SA, Zaki ME. Recent advances in stem cell therapy: efficacy, ethics, safety concerns, and future directions focusing on neurodegenerative disorders–a review. International Journal of Surgery. 2024 Oct 1;110(10):6367-81.

65. Spits C. Stem cell therapy: facts and fiction. Facts, views & vision in ObGyn. 2012;4(3):195.

66. O'Connell AE, Guseh S, Lapteva L, Cummings CL, Wilkins-Haug L, Chan J, Peranteau WH, Almeida-Porada G, Kourembanas S. Gene and stem cell therapies for fetal care: a review. JAMA pediatrics. 2020 Oct 1;174(10):985-91.

67. Ezzati M, Izadpanah M, Hawkins SM, Yalameha B. Advancements in Ovarian Tissue Engineering: Strategies for Fertility Preservation and Restoration: Ovarian Tissue Engineering. Regenerative Engineering and Translational Medicine. 2025 Sep 2:1-20.

68. Hussen BM, Taheri M, Yashooa RK, Abdullah GH, Abdullah SR, Kheder RK, Mustafa SA. Revolutionizing medicine: recent developments and future prospects in stem-cell therapy. International Journal of Surgery. 2024 Dec 1;110(12):8002-24.

69. Sylvester KG, Longaker MT. Stem cells: review and update. Archives of surgery. 2004 Jan 1;139(1):93-9.

70. Nelson TJ, Behfar A, Yamada S, Martinez-Fernandez A, Terzic A. Stem cell platforms for regenerative medicine. Clinical and translational science. 2009 Jun;2(3):222-7..

.